NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Axonis Therapeutics

Axonis Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://axonis.us/

Last Round

Series A

Oct 30, 2024

Total Funding Raised

$141.7M

Company Overview

Axonis Therapeutics is a biotechnology company developing first-in-class oral small molecule therapies targeting KCC2 to treat central nervous system disorders such as epilepsy, chronic pain, and spinal cord injuries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

neuromedicinebiotechnologydrug discoveryneurological disordersbiotech startupclinical-stagetherapeutic candidatesKCC2-targetingdrug developmentbiopharmasmall business innovation researchSBIRnon-dilutive funding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Axonis Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Axonis Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Axonis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 30, 2024
GrantSep 1, 2024
SeedJul 14, 2021
SeedMay 28, 2020

Key People

Founding team and executive leadership

Patrick J. Carew

Chief Operating Officer (COO) Board Member (Founder)

Founding Team

Shane Hegarty

Chief Scientific Officer Co-Founder

Founding Team

Joanna Stanicka

Chief Executive Officer

Executive Team

Axonis Therapeutics Investors

Notable investors and investment history

Axonis Therapeutics investors
InvestorRounds
Iaso VenturesSeries A
SCI VenturesSeries A
CURE EpilepsyGrant
Perceptive AdvisorsSeries A
AcksSeries A
NIH RADxGrant
Cormorant Asset ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 15, 2025

    Translating discoveries from Boston Children's Hospital, Harvard, and Laval University.

  • Jul 3, 2025

    Grew 3D brain organoids in space to test new neurological drugs.

Axonis Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Axonis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Axonis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range26
Year Founded2019
Last FundingOct 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.